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Abstract
Background: During the follow-up of differentiated thyroid cancer patients, the presence of thyroglobulin
antibodies makes thyroglobulin measurements unreliable. For this reason, thyroglobulin antibodies measurement
and the evaluation of their titer trend are also recommended.
Objective: We aimed to identify the best method among stimulated thyroglobulin, thyroglobulin antibodies titer
trend, neck ultrasound and diagnostic whole body scan for detecting the presence of disease in a group of
differentiated thyroid cancer patients with thyroglobulin antibodies.
Patients and methods: We retrospectively reviewed the data of 212 consecutive differentiated thyroid cancer
patients with thyroglobulin antibodies referred to us between 2005 and 2007 for performing a diagnostic whole body
scan. All patients were evaluated during the first two years after the initial treatment.
Results: Diagnostic whole body scan sensitivity and specificity in detecting persistent diseases were 70% and
72%, respectively. Diagnostic whole body scan alone had the best positive and negative predictive values (93% and
32%, respectively). A low sensitivity and specificity (56% and 10%, respectively) for increasing or stable
thyroglobulin antibodies titer trends were also identified. A good compromise between sensitivity and specificity was
obtained when diagnostic whole body scan, stimulated thyroglobulin and neck ultrasound were combined without
considering thyroglobulin antibodies trend evaluations (82% and 45%, respectively).
Conclusions: Diagnostic whole body scan plays an important role in detecting persistent disease in differentiated
thyroid cancer patients with thyroglobulin antibodies, both alone and in association with other methods. However, its
low negative predictive value suggests that when a suspicious persistent disease is present, the use of other
imaging methods, such as computed tomography scan or FDG-positron emission computed tomography, is
recommended. Finally, from this study, it appears that the thyroglobulin antibodies titer trend does not add any useful
information about the disease status in the first two years after initial treatment.
Keywords: Differentiated thyroid cancer; Thyroglobulin antibodies;
Diagnostic whole body scan; Thyroglobulin
Abbreviations: DTC: differentiated thyroid cancer; TgAb:
thyroglobulin antibodies: Tg: thyroglobulin; US: neck ultrasound; dx-
WBS: diagnostic whole body scan; PPV: positive predictive value;
NPV: negative predictive value; rh-TSH: recombinant human thyroid
stimulating hormone; pt-WBS: post high 131I activity whole body
scan.
Introduction
The presence of serum thyroglobulin antibodies (TgAb) has been
reported in approximately 25% of patients with differentiated thyroid
cancer (DTC) [1,2] and in only 10% of the general population [3].
During DTC patient follow-up, the presence of TgAb makes
thyroglobulin (Tg) measurements unreliable because it either
underestimates Tg levels when common Tg-immunometric assays
(IRMA) are used or overestimates Tg levels when less common Tg-
radioimmunoassay methods (RIA) are employed [4,5]. To reduce but
not eliminate the presence of the above-described interference, the
current guidelines for the management of DTC patients strongly
recommend the measurement of TgAb with every measurement of Tg,
ideally in the same laboratory and using the same assay [6,7].
It is conceivable that the presence of benign/metastatic thyroid
tissue is the reason for the persistent synthesis of TgAb [8,10]. Thus, in
patients with DTC and TgAb positive, antibody titer may be used as an
imprecise surrogate for persistent thyroid tissue as either normal or
tumoral [11]. According to this concept, a decrease in the TgAb titer
trend can be interpreted as a reduction in the residual disease, with no
further imaging methods [except neck ultrasound (US)] being
required. In contrast, when an increasing or stable titer trend is
identified, in addition to neck US, an 131I (or if available 123I or 124I)
diagnostic whole-body scan (dx-WBS) can be helpful for identifying
persistent or recurrent disease [6,11]. However, the practical usefulness
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of dx-WBS is still a matter of discussion, particularly in patients
without TgAb but also in those with TgAb as there are some studies
showing that dx-WBS is a prognostically and diagnostically useful
procedure [12,13] and others showing that it is less usefull [14,15].
In this study, we evaluated the diagnostic accuracy of dx-WBS
performed 6 months after radioiodine ablation in 212 DTC patients
with TgAb. dx-WBS specificity, sensitivity, positive and negative
predictive values (PPV and NPV, respectively) were also calculated and
compared with those of stimulated Tg, TgAb titer trends and neck US
to identify which among them represents the best method for detecting
the presence of persistent disease or thyroid remnants, as assessed by




We retrospectively reviewed the clinical and pathological data of
212 consecutive patients, including 169 females (80%) and 43 males
(20%) (M:F=1:4), with DTC and TgAb referred to the Department of
Endocrinology in Pisa between 2005 and 2007 for 131I dx-WBS after
recombinant human thyroid stimulating hormone (rh-TSH)
administration (204 patients, 96%) or thyroid hormone withdrawal (8
patients, 4%). The mean age at diagnosis of all patients was 41 ± 13.7
years (range: 9-77 years; median: 40 years).
The histotype was papillary in 210 patients (99%) and follicular in
the remaining 2 cases (1%). Histological variant information regarding
papillary histotype patients were available for 159/212 patients (75%):
69 patients had the classical variant (43%), 45 had the follicular variant
(28%) and the remaining 45 patients had less frequent histological and
more aggressive variants (29%).
Despite the presence of serum TgAb in all cases (criteria for
inclusion in the study group), the presence of focal or diffuse
histological thyroiditis was identified in 107 patients (50%). At the time
of diagnosis, lymph node metastases were found in 84/212 patients
(40%).
All selected patients underwent treatment according to our
traditional protocol that requires a total thyroidectomy [141 patients
(66.7%) underwent thyroidectomy at the Department of Surgery of
Pisa, 71 patients (33.3%) were referred to our Department after have
the surgery performed elsewhere], followed by remnant thyroid
ablation with 1,110 MBq to 3,700 MBq of 131I.
Approximately 6 months after the radio-iodine (131I) ablation,
patients were examined through a clinical and hormonal assessment,
neck ultrasound and dx-WBS to establish the subsequent follow-up. A
subgroup of 68 of the 212 patients (32%) underwent one or further
radiometabolic treatment(s) with high 131I activity according to the
results of the first control performed 6 months after the initial
treatment.
The study was approved by the Institutional Reviewing Board and
all patients gave consent to participate in the study.
Methods
Tg measurement
Serum Tg measurement, either after L-T4 withdrawal or rh-TSH
administration, was performed in the same laboratory for all patients.
A sensitive immunometric method with a functional sensitivity of 0.9
ng/ml (Immulite 2000 Thyroglobulin, Diagnostic Product
Corporation, Los Angeles, CA) was used.
Tg stimulation was performed via administration of rh-TSH [one
injection of rh-TSH (0.9 mg i.m.; Thyrogen, Genzyme Corp.,
Cambridge, MA) for 2 consecutive days] and in a small percentage of
cases by withdrawing L-T4 therapy one month before evaluation.
TSH and Tg serum sample measurements were collected before the
first rh-TSH injection and during the following days up to day 5.
TgAb and TgAb titer trend evaluation measurements
The circulating TgAb measurement was determined in the same
laboratory for all patients using an immunofluorimetric method (AIA-
Pack TgAb Tosoh Corporation, Tokyo, Japan) [normal range: 0 U/ml
to 30 U/ml, coefficient of variation (CV) varying between 10.5% and
17.7% depending on the titer].
In our study, we considered TgAb<20 IU/ml a negative titer after we
had demonstrated in our laboratory that the interference of TgAb in
the Tg assay begin when the TgAb values were>20 IU/ml (data not
shown).
To define an increasing or decreasing TgAb titer trend, we
considered a change as significant when the difference between the two
measurements was more than 50% in either direction. This choice was
based on a formula described by experts in a recent clinical position
statement on the management of patients with DTC and TgAb
positivity [11].
dx-WBS and pt-WBS
As indicated in the clinical position statement for the follow-up of
the patients with DTC and TgAb [11], the entire group was submitted
to dx-WBS [204/212 patients (96%) with euthyroidism after rh-TSH
stimulation and 8 patients (4%) after discontinuation of L-T4 therapy].
WBS was performed using a one-head γ-camera (Apex SPX 4000,
Elscint Italia, Milano, Italy) with a high-energy collimator and a
sensitivity of 160 cpm/μCi. The scan speed was 10 cm/min with a total
count of at least 100,000 cpm.
dx-WBS was performed 48 hours after administration of a 148 MBq
tracer dose of 131I. WBS after 131I therapeutic doses (pt-WBS) (3,330
MBq to 5,550 MBq) was performed 5 days to 10 days after 131I
administration.
Neck ultrasound
Neck US was performed using a color Doppler apparatus (AU 590
Asynchronous, Esaote Biomedica, Firenze, Italy). Central, latero-
cervical and supraclavear lymph node compartments were also
evaluated to exclude the presence of suspicious lymph nodes and,
whenever present, a fine needle aspiration biopsy and a Tg
measurement of the washing fluid were performed.
Statistical analysis
Data were presented as the mean ± the standard deviation (SD) and
the median with an interquartile range (IQR). Sensitivity, specificity
and PPV and NPV were calculated for dx-WBS, neck US, stimulated
Tg and TgAb titer trend in relation to the pt-WBS status.
For each parameter, logistic regression analysis was also conducted
to estimate the odds ratios (OR) and the 95% confidence interval (CI).
A p-value less than 0.05 was considered statistically significant.
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Results
Results of basal and stimulated Tg, neck US, dx-WBS and TgAb
titer trend
All patients of the study group (n=212) showed undetectable basal
Tg level. The TgAb serum mean titer of the entire group was 182.18
IU/ml ± 237 IU/ml (range: 24 IU/ml to 1663 IU/ml, median: 87 IU/
ml). As shown in Table 1, stimulated Tg was detectable in 19/212
patients (9%) (18/204 of those stimulated by rh-TSH and 1/8 of those
stimulated by L-T4 withdrawal). The mean Tg peak was 4.2 ± 6.0

























64 (30) - - - +
55 (26) - - - -
27 (13) - - + -
22 (10) - - + +
9 (4) + - - +
8 (4) - + - +
6 (3) - + + +
6 (3) + - + +
5 (2) - + - -
4 (2) - + + -
2 (1) + - - -
1 (0.5) + + + +
1 (0.5) + - + -
1 (0.5) - - - unknown
1 (0.5) - - + unknown
+: positive; -: negative; * Basal Tg was undetectable in all 212 patients
Table 1: Combination of the results of basal and stimulated
thyroglobulin (Tg), neck ultrasound (US), diagnostic whole body-scan
(dx-WBS) and thyroglobulin antibodies (TgAb) titer trend in the study
group (n=212).
The neck US identified 24/212 (11.3%) positive cases. In particular:
14/24 patients (58.3%) had remnant thyroid tissue, 2/24 (8.3%) had
persistent local disease and 8/24 (33.4%) had cervical lymph node
metastases. Cytological examination of the fine needle aspiration
biopsies and Tg measurements on washing fluid confirmed the disease
diagnoses in the 2 cases with persistence and in the 8 cases with
cervical lymph node metastases (Table 1). The dx-WBS showed 131I
uptake in 68/212 cases (32.1%). In particular 131I uptake showed a
thyroid remnant tissue in 59/68 patients (86.8%), cervical lymph node
metastases in 3/68 patients (4.4%), lung metastases in 3/68 patients
(4.4%) and lymph node in the mediastinal region in 3/68 patients
(4.4%). The dx-WBS was negative in the remaining 144/212 cases
(67.9%). TgAb titer trend was reduced in 94/212 patients (44.3%),
increased in 36 patients (17%) and stable in 80 patients (37.7%). This
information was not available for 2 cases (1%) (Table).
pt-WBS results
As shown in Figure 1, 68/212 patients (32%) underwent at least a
second 131I treatment. Among them 43 were positive at dx-WBS while
25 were negative and treated for other reasons such as a positive
stimulated Tg and/or an increasing/stable TgAb titer trend and/or a
positive neck US. In some cases a combination of these methods was
suggesting the opportunity to treat the patients (Figure 1).
Figure 1: Positive imaging and/or biochemical tests that provided a
basis for which patients underwent further treatments with high
activities of 131I.
Figure 2: Post high 131I activity whole body scan (pt-WBS) results.
The majority of the cases (n=44) were positive only for thyroid bed
uptake, which is likely due to post-surgical thyroid remnants.
As shown in Figure 2, the pt-WBS showed the presence of remnant
thyroid tissue in 44 patients (65%) and it was negative in 11 patients
(16%). The remaining 13 patients (19%) had 131I uptake at pt-WBS in
different regions outside the thyroid bed.
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Comparison between pt-WBS and other methods results
As shown in Table 2, stimulated Tg and pt-WBS were both positive
or both negative in 14 cases (true positive cases: 12-21; true negative
cases: 8-11). In 7 cases they were discordant likely due to false
positivity of stimulated Tg (cases 1-7). In 47 cases the two methods
were discordant likely for a low sensitivity of stimulated Tg (cases
22-68).
Patients Stimulated Tg pt-WBS
01-Jul Positive Negative
08-Nov Negative Negative
12 Positive Mediastinal 131I uptake
13 Positive Remnant tissue and lung mets
14-21 Positive Remnant tissue
22-23 Negative Remnant tissue and lymph node mets
24-25 Negative Remnant tissue and mediastinal 131I uptake
26 Negative Mediastinal 131I uptake
27-29 Negative Lymph node mets
30 Negative Lymph node mets and mediastinal 131I uptake
31-32 Negative Lung mets
33-68 Negative Remnant tissue
Table 2: results of post high 131I activity whole body scan (pt-WBS)
compared to stimulated thyroglobulin (Tg).
Patients Neck US pt- WBS
1-2 Lymph node mets Remnant tissue
3-4 Lymph node mets Lymph node mets
5-6 Lymph node mets Remnant tissue and lymph node mets
7 Lymph node mets Lung mets
8-43 Negative Remnant tissue
44-53 Negative Negative
54-55 Negative Mediastinal 131I uptake
56 Negative Remnant tissue and lung mets
57 Negative Remnant tissue and mediastinal 131I uptake
58 Negative Lymph node mets and mediastinal 131I uptake
59 Negative Lung mets
60 Negative Lymph node mets
61-66 Remnant tissue Remnant tissue
67 Remnant tissue Negative
68 Remnant tissue Remnant tissue and mediastinal 131I uptake
Table 3: results of post high 131I activity whole body scan (pt-WBS)




1-3 Cervical Uptake (possible
lymph node mets)
Remnant tissue
4 Remnant tissue + mediastinal
131I uptake
Remnant tissue
5-6 Mediastinal 131I uptake Mediastinal 131I uptake
7-8 Lung mets Lung mets
9 Lung mets Negative
10-38 Remnant tissue Remnant tissue
39-40 Remnant tissue Remnant tissue and lymph node
mets
41 Remnant tissue Remnant tissue and lung mets
42-43 Remnant tissue Negative
44-51 Negative Negative
52-54 Negative Lymph node mets
55 Negative Lymph node mets and
mediastinal 131I uptake
56-57 Negative Remnant tissue and mediastinal
131I uptake
58-68 Negative Remnant tissue
Table 4: results of post high 131I activity whole body scan (pt-WBS)
compared to the diagnostic whole body scan (dx-WBS) results.
Patients TgAb titer trend pt- WBS
1-9 Increasing/stable Negative
10 Decreasing Negative
11 Decreasing Lymph node mets
12 Decreasing Remnant tissue and mediastinal 131I uptake
13-35 Decreasing Remnant tissue
36-37 Increasing/stable Mediastinal 131I uptake
38-39 Increasing/stable Lymph node mets
40 Increasing/stable Lymph node mets and mediastinal 131I uptake
41-42 Increasing/stable Lung mets
43 Increasing/stable Remnant tissue and and mediastinal 131I uptake
44-45 Increasing/stable Remnant tissue and lymph node mets
46 Increasing/stable Remnant tissue and lung mets
47-67 Increasing/stable Remnant tissue
* Information about TgAb trend was available in 67/68 treated patients.
Table 5: results of post high 131I activity whole body scan (pt-WBS)
compared to thyroglobulin antibodies (TgAb) titer trend evaluation.
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As shown in Table 3, neck US and pt-WBS were both positive and
both negative in 24 cases (true positive cases: 1-7, 61-66 and 68; true
negative cases: 44-53). In 1 case they were discordant likely due to a
false positivity of neck US (case 67). In 43 cases the two methods were
discordant likely for a low sensitivity of stimulated Tg (cases 8-43 and
54-60).
As reported in Table 4, dx-WBS and pt-WBS were both positive and
both negative in 48 cases (true positive cases: 1-8 and 10-41; true
negative cases: 44-51).
In 3 cases they were discordant likely due to a false positive dx-WBS
(cases 9 and 42-43). In 17 cases the two methods were discordant likely
for a low sensitivity of dx-WBS (cases 52-68).
As shown in Table 5, TgAb titer trend evaluation and pt-WBS were
both positive and both negative in 33 cases (true positive cases: 36-67;
true negative cases: 10).
In 9 cases they were discordant likely due to a false positivity of
TgAb titer trend (cases 1-9). In 25 cases the two methods were
discordant likely for a low sensitivity of TgAb titer trend (cases 11-35).
A summary of true and false positive and true and false negative
cases of the four methods was reported in Table 6.
 True positive cases (%) False positive cases (%) True negative cases (%) False negative cases (%)
dx-WBS 40/68 (59) 3/68 (4) 8/68 (12) 17/68 (25)
Stimulated Tg 10/68 (15) 7/68 (10) 4/68 (6) 47/68 (69)
Neck US 14/68 (21) 1/68 (1) 10/68 (15) 43/68 (63)
TgAb titer trend 32/67* (48) 9/67* (13) 1/67* (2) 25/67* (37)
* information about TgAb trend was available in 67/68 treated patients
Table 6: summary of true positive, false positive, true negative and false negative cases of diagnostic whole body scan (dx-WBS), simulated
thyroglobulin (Tg), neck ultrasound (US) and thyroglobulin antibodies (TgAb) titer trend evaluation.
Sensitivity, specificity, and positive and negative predictive
values for dx-WBS and other diagnostic methods
The sensitivity, specificity, PPV and NPV for dx-WBS and other
diagnostic methods are reported in Table 7. dx-WBS sensitivity and
specificity were 70% and 72%, respectively. Neck US was the only
method with a greater specificity than dx-WBS (91% vs 72%), although
it had a lower sensitivity (24%).
As expected, based on the TgAb positivity, stimulated Tg sensitivity
was confirmed to be very low in this study group (18%). The low
sensitivity and specificity (56% and 10%, respectively) for the
increasing or stable TgAb titer trend when it was considered alone
should also be noted.








dx-WBS 70 (57-81) 72 (39-94) 93 (81-98) 32 (15-53)
Stimulated Tg 18 (9-30) 63 (31-89) 71 (42-92) 13 (5-25)
Neck US 24 (14-38) 91 (59-100) 93 (68-100) 18 (9-32)
TgAb titer trend 56 (42-69) 10 (0-44) 78 (62-89) 4 (0-20)
Stimulated Tg+dx-WBS 75 (62-86) 45 (17-77) 88 (75-95) 26 (9-51)
Stimulated Tg+neck US 42 (29-56) 64 (31-89) 86 (67-96) 18 (7-33)
TgAb titer trend+dx-WBS 88 (76-94) 0 (0-31) 83 (71-92) 0 (0-41)
TgAb titer trend+neck US 65 (51-77) 10 (0-44) 80 (66-91) 5 (0-24)
dx-WBS+stimulated Tg+neck US 82 (70-91) 45 (17-77) 89 (77-96) 33 (12-62)
dx-WBS+stimulated Tg+neck US+TgAb titer
trend
93 (83-98) 0 (0-31) 84 (73-92) 0 (0-60)
Table 7: sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and 95% intervals of confidence (CI) of
diagnostic whole body scan (dx-WBS), stimulated thyroglobulin (Tg), thyroglobulin antibodies (TgAb) titer trend (increasing/stable) and neck
ultrasound (US) considered alone and in combination with each other.
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Although sensitivity increased from 70% to 93% when dx-WBS was
associated with stimulated Tg measurements, TgAb titer trend
evaluations and neck US, the best single method able to detect post-
treatment 131I uptake was dx-WBS (OR=6.3, 95% CI: 1.48 to 26.6,
p=0.01).
Stimulated Tg, neck US and TgAb titer trend evaluation were not
statistically significant to detect patients with post-treatment 131I
uptake (p=0.17, p=0.28, and p=0.07, respectively).
Discussion
The important role of serum Tg as a post-operative biochemical
tumor-marker in patients with DTC has been well-established. In
particular its high sensitivity and NPV when used in conjunction with
neck US for disease detection has been proved [14]. One major
limitation in its use due to interference from TgAb, which are found in
approximately 25% of DTC patients. Based on this interference,
current guidelines for the management of DTC patients recommend a
TgAb measurement with every Tg measurement [6].
Because TgAb positivity makes Tg values unreliable for
understanding disease status, a group of experts recently proposed a
clinical position statement where they suggest the use of the TgAb titer
as a surrogate marker for the disease. In particular, they suggest the
evaluation of the titer trend during DTC patient follow-ups. For this
subgroup of patients, in addition to the TgAb titer trend evaluation
and neck US, dx-WBS is also suggested to detect structural disease,
especially outside the thyroid bed [11].
The aim of our study was to identify the best method among
stimulated Tg, TgAb titer trend, neck US and dx-WBS for detecting
the presence of persistent diseases in a group of DTC patients with
TgAb.
Our study demonstrated that stimulated Tg (either after levo-
tyroxine withdrawal or rh-TSH stimulation) was detectable in 9% of
patients despite TgAb positivity at the first control after the initial
treatment (i.e. total thyroidectomy and thyroid remnant ablation with
131I). This finding showed that in some cases, despite the presence of
high TgAb levels, the interference is not complete and serum Tg can be
detected, especially after TSH stimulation [16,17]. However, the grade
of TgAb interference cannot be quantified and the Tg measurements
for this subgroup of patients remains unreliable for identifying cured
DTC patients, although its positive diagnostic role has been confirmed.
Because the neck is the most frequent site for persistent/recurrent
disease in DTC patients, it is well-established that neck US is the best
method to detect local persistent disease or the persistence of lymph
node metastases [18]. In our study, although neck US had a very low
NPV, which is primarily due to its inability to detect metastatic disease
outside of the neck, it had a high PPV (93%), confirming that it is also
a good method for detecting neck disease/remnant thyroid tissue in
this subgroup of patients. It should also be taken into account that,
when a suspicious lesion is found by neck US, a confirming diagnosis
can be obtained with a fine needle aspiration biopsy and a Tg
measurement from the washing fluid. Our study, as well as other
previous studies [19], has identified no relevant TgAb interference to
Tg measurements in the washing fluid. It should also be kept in mind
that small lymph nodes metastases (cases 7 and 58 of our series) may
not be able to take up 131I, but their metastatic nature, as reported
above, can be confirmed by cytology and Tg measurement in the
washing fluid.
Regarding the TgAb titer trend, 44.5% of patients had a decreasing
titer trend and 54.5% had an increasing/stable titer trend. In particular,
an increasing/stable titer trend alone was found in 30% of patients,
while in the remaining 24.7% it was associated with at least one other
positive method (10% with positive dx-WBS and 14.7% with positivity
based on the other methods considered). When the TgAb titer trend
was considered alone, a high PPV was identified (78%) despite the low
NPV (4%). In our opinion, the low NPV can be explained with results
obtained in a previous study by Chiovato et al. [20]. These authors
demonstrated that the persistence of thyroid autoimmunity remains
until the complete removal of thyroid antigens (represented by both
normal and tumoral thyroid cells); the median disappearance time for
TgAb is 3 years. In some unpublished data, we have also observed that
some DTC patients need several years (up to 20) for total TgAb
disappearance in the absence of active therapy. In the present study,
especially for those patients with a stable titer trend, the time interval
between the initial treatment and our observation was probably not
enough to allow a significant decrease in TgAb, as suggested by
Chiovato et al. [20]. When the TgAb titer trend evaluation was
associated with dx-WBS, the PPV increased to 83% at the expense of
the NPV, which was further reduced. In the same way, when the TgAb
titer trend was associated with neck US, the PPV was higher than
when the TgAb titer trend was considered alone.
dx-WBS is no longer used in the follow-up for patients with low-
risk DTC because it is less sensitive than serum stimulated Tg [21].
However, this is applicable only when the Tg levels, both basal and
after endogenous or exogenous TSH stimulation, were reliable and
thus, in the absence of TgAb interference. As indicated in the current
guidelines [6], dx-WBS still plays an important role in DTC patients
with TgAb and this was confirmed by our study. In fact, dx-WBS was
able to detect 40/68 (59%) true positive cases, including 2 patients with
mediastinal 131I uptake and 2 patients with lung disease.
According to these results, dx-WBS showed the best combination
between sensitivity and specificity (70% and 72%, respectively) and
between PPV and NPV (93% and 32%, respectively). It should be
noted that only when we considered all four methods together did the
sensitivity increase up to 93%, although at the expense of specificity.
Similar to the findings of Rosario et al. [13], we found that the
combination of dx-WBS, stimulated Tg and neck US without TgAb
titer trend showed the best compromise between sensitivity and
specificity. This result is in contrast with the suggestion of experts to
use TgAb trend as a surrogate for serum Tg. Very likely, the use of the
TgAb trend is more useful during long-term follow-up than
immediately after the initial treatment for the reasons mentioned
above.
A main limitation of this study is that we considered a 131I uptake in
the thyroid bed a positive result and 12 patients were treated only for
this reason. Whether 131I uptake limited at the thyroid bed requires or
not to be always treated is still a matter of discussion. The 131I
treatment should be better reserved to cases with 131I uptake due to
lymphnodes metastases other than to normal remnant. Since the
planar WBS cannot distinguish the uptake due to the remnant from
those due to small local lymphnodes, the use of single photon emission
computed tomography/computed tomography (SPECT-CT) is strongly
suggested since it allows a better identification of the uptake site, as it
has been recently demonstrated [22,23].
In conclusion, the present study demonstrated that dx-WBS plays
an important role in detecting DTC patients with circulating TgAb
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that need a further 131I treatment, either when it is considered alone or
in association with other methods and particularly during the first
couple of years of follow-up. However, when a suspicious persistent
disease is present and the dx-WBS is negative, other imaging methods,
such as a CT scan or FDG-PET, should be considered. Finally, from
this study, it appears that the TgAb titer trend does not add any useful
information about the disease status in the first two years after initial
treatment.
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